Inability to control autoimmunity is the primary barrier to developing a cure for type 1 diabetes (T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clones offers promise for a new approach to overcome the autoimmunity underlying T1D.
We developed a procedure for Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop system that separate lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them to the patient’s circulation. In an open-label,
A particular type of stem cell transplantation using the patient’s own cells led to short-term freedom from insulin injections in 20 of 23 patients newly diagnosed with type 1 diabetes participating in an experimental protocol in Brazil.
One patient even managed to go four years without needing outside sources of insulin, although the average was 31 months, said the authors of a report in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes.
The patients also kept their blood sugar under control, which is key to preventing complications from diabetes. And, the authors
A team of researchers has brought the end of diabetes closer to reality by announcing a new breakthrough that could lead directly to a cure and not just a treatment for the disease.
The scientists discovered a protein that activates the maturation process in vitro, overcoming this longstanding obstacle in diabetes therapy development.
“In a dish, with this one switch, it’s possible to produce a functional human beta cell that’s responding almost as well as the natural thing,” says senior author Ronald Evans of the Salk Institute. “This has been a major blockade, and overcoming it has been a major challenge
Scientists said on Monday they had used cloning technology to make embryonic stem cells that carry a diabetic woman’s genes, and turned them into insulin-producing beta cells that may one day cure her disease.
The team reported clearing an important hurdle in the quest to make “personalised stem cells” for use in disease therapy, but a bioethicist said the breakthrough also highlighted the need for better regulation of lab-grown embryos.
“We are now one step closer to being able to treat diabetic patients with their own insulin-producing cells,” said Dieter Egli of the New York Stem Cell Foundation (NYSCF), who led